LYEL

Lyell Immunopharma Inc

LYEL, USA

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity; and Stim-R, a proprietary synthetic-cell mimetic. It is also developing IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate that is in Phase 1/2 clinical development for the treatment of patients with aggressive relapsed/refractory large B-cell non-Hodgkin lymphoma; and solid tumors program which is in preclinical trial targeting solid tumor indications. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

https://www.lyell.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
LYEL
stock
LYEL

1,820,634 Shares in Lyell Immunopharma, Inc. $LYEL Bought by ARCH Venture Management LLC Defense World

Read more →
LYEL
stock
LYEL

Lyell Immunopharma (NASDAQ:LYEL) Sets New 12-Month High - Should You Buy? MarketBeat

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

HOLD

Target Price:

$19

Analyst Picks

Strong Buy

0

Buy

0

Hold

3

Sell

1

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Medium

1.91

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-11.80 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-9.52 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-190,926.67 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very High

0.24

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 48.69% of the total shares of Lyell Immunopharma Inc

1.

ARCH VENTURE CORP

(9.4769%)

since

2025/06/30

2.

MWG Management Ltd.

(5.2475%)

since

2025/03/31

3.

Foresite Capital Management IV, LLC

(4.1663%)

since

2025/06/30

4.

Orland Properties Ltd

(3.9284%)

since

2025/03/31

5.

Decheng Capital LLC

(3.0996%)

since

2025/03/31

6.

Almitas Capital LLC

(3.0191%)

since

2025/06/30

7.

venBio Partners LLC

(2.4646%)

since

2025/06/30

8.

Vanguard Group Inc

(2.304%)

since

2025/06/30

9.

Foresite Capital Management V, LLC

(2.1167%)

since

2025/06/30

10.

T. Rowe Price Associates, Inc.

(1.5931%)

since

2025/06/30

11.

Alphabet Inc

(1.5265%)

since

2025/06/30

12.

Vanguard Total Stock Mkt Idx Inv

(1.4373%)

since

2025/07/31

13.

Citadel Advisors Llc

(1.4121%)

since

2025/06/30

14.

T. Rowe Price Health Sciences

(1.1045%)

since

2025/07/31

15.

SC China Holding Ltd

(0.7928%)

since

2025/06/30

16.

BlackRock Inc

(0.754%)

since

2025/06/30

17.

Geode Capital Management, LLC

(0.5376%)

since

2025/06/30

18.

RBF LLC

(0.5205%)

since

2025/06/30

19.

Woodline Partners LP

(0.5123%)

since

2025/06/30

20.

Vanguard Institutional Extnd Mkt Idx Tr

(0.4773%)

since

2025/07/31

21.

Fidelity Extended Market Index

(0.2639%)

since

2025/07/31

22.

Schwab US Small-Cap ETFâ„¢

(0.23%)

since

2025/08/30

23.

Johnson & Johnson

(0.2143%)

since

2025/03/31

24.

Takeda Pharmaceutical Co Ltd

(0.2143%)

since

2025/03/31

25.

iShares Biotechnology ETF

(0.1817%)

since

2025/08/31

26.

TD Health Sciences - I

(0.1307%)

since

2024/12/31

27.

SEI Tax-Managed Small/Mid Cap F (SIMT)

(0.1105%)

since

2025/08/31

28.

Bridgeway Ultra-Small Company Market

(0.0937%)

since

2025/06/30

29.

Goldman Sachs Asset Management, L.P.

(0.0933%)

since

2025/03/31

30.

Fidelity Total Market Index

(0.0927%)

since

2025/07/31

31.

Extended Equity Market Fund K

(0.0901%)

since

2025/06/30

32.

Vanguard Health Care ETF

(0.0887%)

since

2025/07/31

33.

T. Rowe Price Health Sciences Port

(0.0743%)

since

2025/07/31

34.

Fidelity Series Total Market Index

(0.0679%)

since

2025/07/31

35.

Invesco RAFI US 1500 Small-Mid ETF

(0.0622%)

since

2025/08/29

36.

Galileo - Biotech Innovation Fund S USD

(0.0521%)

since

2025/02/28

37.

NT Col R2000 Val Idx Fd -DC -L -TierFour

(0.0471%)

since

2025/03/31

38.

JHFunds2 Health Sciences NAV

(0.0362%)

since

2025/01/31

39.

Vanguard Instl Ttl Stck Mkt Idx Tr

(0.0325%)

since

2024/12/31

40.

State Street Russell 2000 Value CIT

(0.0203%)

since

2025/03/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-2.13

EPS Estimate

-2.6425

EPS Difference

0.5125

Surprise Percent

19.3945%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(4.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Fair GARP(4.5)
Growth
Weak Growth Prospect(3)
Momentum
No Momentum(2)
Net Net
Not Undervalued (Net-Net)(3)
Quality
Low Quality Business(2.5)
Value
Fair Value(6)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.